Goodwill and Other Intangible Assets, Net

6 Months Ended

Oct. 25, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets, Net

The changes in the carrying amount of goodwill for the six months ended October 25, 2013 are as follows:



(in millions)	Cardiac and Vascular Group		Restorative Therapies Group		Diabetes Group		Total
Balance as of April 26, 2013	$	2,624	$	6,361	$	1,344	$	10,329
Goodwill as a result of acquisitions	123		—		—		123
Currency adjustment, net	1		11		—		12
Balance as of October 25, 2013	$	2,748	$	6,372	$	1,344	$	10,464

Balances of intangible assets, net, excluding goodwill, as of October 25, 2013 and April 26, 2013 are as follows:



(in millions)	Purchased Technology and Patents			Trademarks and Tradenames			Acquired IPR&D		Other			Total
Other intangible assets as of October 25, 2013:
Original cost	$	3,921		$	408		$	325	$	190		$	4,844
Accumulated amortization	(1,825		)	(327		)	—		(84		)	(2,236		)
Carrying value	$	2,096		$	81		$	325	$	106		$	2,608
Other intangible assets as of April 26, 2013:
Original cost	$	3,896		$	408		$	363	$	104		$	4,771
Accumulated amortization	(1,702		)	(320		)	—		(76		)	(2,098		)
Carrying value	$	2,194		$	88		$	363	$	28		$	2,673

Amortization expense for the three and six months ended October 25, 2013 was $88 million and $174 million, respectively, and for the three and six months ended October 26, 2012 was $79 million and $159 million, respectively.

Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets, excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows:



(in millions) Fiscal Year	Estimated Amortization Expense
Remaining 2014	$	174
2015	336
2016	324
2017	302
2018	286
2019	240
Thereafter	621
Total estimated amortization expense	$	2,283

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details